Jazz Pharmaceuticals

Health Care  |  Pharmaceuticals
167.71 1.9 1.15%
Stock Price | Jan. 15, 2021, 4 p.m.
Prev. Close: 165.81
52 Week Low: 86.88
52 Week High: 168.12
PE Ratio: 53.072785
Dividend Yield: %

Company Summary

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Read more Read less

Recently Viewed Tickers

Free Preparing for the Week of May 11

5 years ago
5 years ago